证券代码：000756 证券简称：新华制药 公告编号：2025-25 山东新华制药股份有限公司 三、审议通过关于召开 2024 年度周年股东大会的议案（股东大会通知将另行公告）。 9 名董事赞成本议案，0 票反对，0 票弃权。 备查文件 一、审议通过本公司 2025 年第一季度报告（见同日发布于《证券时报》及巨潮资讯网 （http://www.cninfo.com.cn）公告）； 9 名董事赞成本议案，0 票反对，0 票弃权。 二 、 审 议 通 过 了 2024 年 环 境 、 社 会 及 管 治 报 告 （ 见 同 日 发 布 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn）公告）。 9 名董事赞成本议案，0 票反对，0 票弃权。 第十一届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 山东新华制药股份有限公司（"本公司"）第十一届董事会第七次会议通知于二零二五年四 月十四日以电邮方式发出，会议于二零二五年四月二十八日在山东省淄博市高新区鲁泰大道 1 号公司会议室召开，应到会董事 9 名，实际参会董事 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥2,429,825,335.81, a decrease of 1.81% compared to ¥2,474,697,457.66 in the same period last year[5] - Net profit attributable to shareholders was ¥112,095,257.24, down 20.99% from ¥141,879,437.62 year-on-year[5] - Basic and diluted earnings per share were both ¥0.15, representing a decline of 28.57% from ¥0.21 in the same period last year[5] - Total comprehensive income for the current period was 104,998,682.16, down from 146,079,426.17 in the previous period, a decrease of about 28.2%[20] - Net profit for the current period was 115,643,803.12, down from 145,264,098.40 in the previous period, representing a decrease of approximately 20.4%[19] Cash Flow and Operating Activities - The net cash flow from operating activities decreased by 77.87%, amounting to ¥8,425,190.10 compared to ¥38,063,364.43 in the previous year[5] - Cash flow from operating activities generated a net amount of 8,425,190.10, significantly lower than 38,063,364.43 in the previous period[21] - The decline in net cash flow from operating activities was attributed to an increase in the proportion of bank acceptance bill collections and a decrease in inventory changes compared to the previous year[8] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,269,855,861.11, an increase of 2.77% from ¥9,019,601,567.53 at the end of the previous year[5] - The total current assets increased to ¥3,999,396,150.59 from ¥3,726,840,162.91, reflecting a growth of about 7.3%[16] - Accounts receivable rose significantly to ¥1,200,307,190.06, up from ¥868,204,001.79, indicating an increase of approximately 38.2%[16] - The total liabilities increased to ¥3,879,907,761.23 from ¥3,802,101,150.19, marking a rise of about 2.0%[17] - The non-current liabilities decreased to ¥645,097,935.77 from ¥1,006,487,037.80, a reduction of approximately 35.9%[17] Shareholder Equity - Shareholders' equity attributable to the parent company increased by 3.28% to ¥5,155,519,978.65 from ¥4,991,588,524.78[5] - The total equity attributable to shareholders increased to ¥5,155,519,978.65 from ¥4,991,588,524.78, indicating a growth of approximately 3.3%[17] Expenses - Research and development expenses for the current period were 109,788,595.18, compared to 141,905,763.44 in the previous period, showing a reduction of approximately 22.6%[19] - The company reported a decrease in sales expenses from 291,064,033.27 in the previous period to 99,952,491.15 in the current period, a reduction of about 65.6%[19] - The company's total operating costs decreased from 2,328,929,009.30 to 2,299,988,387.70, a reduction of approximately 1.2%[19] Other Income and Changes - The company reported non-operating income of ¥7,067,182.83, primarily from government subsidies and asset disposal gains[7] - The company approved changes to accounting policies that are not expected to have a significant impact on the financial statements[13] - The company experienced an investment loss of 760,243.82 in the current period, compared to a gain of 1,188,728.16 in the previous period[19]

Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the supplementary application of Mecobalamin tablets, allowing the transfer of the marketing authorization holder [1] Company Summary - The transaction does not require approval from the company's board of directors or shareholders, as it does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [1] - Mecobalamin tablets are indicated for peripheral neuropathy and are listed as a Class B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog [1] Industry Summary - In 2023, the sales revenue of Mecobalamin tablets in Chinese public medical institutions is approximately RMB 1.431 billion [1]

Group 1: Company Growth and Innovation Strategies - The company is focusing on establishing innovation platforms with renowned research institutions to enhance high-value new drug development and accelerate results transformation [2][3] - There are over 100 drugs in the research pipeline, including multiple first-class innovative drugs like OAB-14 for Alzheimer's treatment [3][4] - The company aims to deepen internationalization and strengthen its position in the high-value raw material drug market [2][3] Group 2: Financial Performance and Market Position - In 2024, the company achieved a revenue of 8.466 billion yuan, representing a year-on-year growth of 4.51% [6][9] - The company emphasizes cash dividends, with the cash dividend ratio significantly exceeding the stipulated proportion in its articles of association [2][3] - The company's price-to-earnings ratio is lower than most pharmaceutical companies, raising concerns about potential stock buybacks [2][6] Group 3: Cost Control and Efficiency Measures - The company implements comprehensive budget management to control expenses and enhance operational efficiency [3][4] - Measures include optimizing procurement processes and production operations to reduce costs while maintaining quality [3][4] Group 4: Market Challenges and Stock Performance - Despite the approval of multiple new products, the stock price has been declining, influenced by market competition, industry policies, and investor sentiment [5][9] - The company acknowledges the impact of macroeconomic uncertainties and competitive pressures on its market value [9][10] Group 5: Investor Relations and Communication - The company is committed to enhancing communication with investors through regular reports and performance briefings [6][9] - The recent investor relations activities aim to rebuild investor confidence and clarify the company's strategic direction [6][9] Group 6: Industry Outlook - The pharmaceutical industry is expected to grow due to increasing health awareness and an aging population, with innovation driving new drug development [11]

Group 1 - The core viewpoint emphasizes the importance of county economies as a foundation for urban economic growth, highlighting the case of Yiyuan as a model for industrial and agricultural development [2][19] - Yiyuan's industrial output has significantly increased from 1 million yuan in 1949 to 38.02 billion yuan currently, showcasing a successful transition from agriculture to a robust industrial base [2][9] - The pharmaceutical company Ruiyang Pharmaceutical is highlighted as a key example of Yiyuan's economic evolution, having grown from a small factory to a leading enterprise in the new pharmaceutical industry [3][5][6] Group 2 - Yiyuan's new pharmaceutical industry has reached a scale of 19.147 billion yuan, becoming a pillar of the local economy alongside new materials, which contribute 13.15 billion yuan [7][9] - In 2024, Yiyuan's GDP is projected to be 37.91 billion yuan, with the new pharmaceutical and new materials industries accounting for 85% of the total GDP, demonstrating their critical role in economic stability [9][19] - The county's economic growth rate of 7.6% in 2024 is above the city average, indicating a strong performance in industrial output and value-added contributions [9][19] Group 3 - The article discusses the challenges faced by Zibo, where the county-level economies are seen as a weakness, lacking strong leadership in economic growth [10][19] - Zibo's GDP in 2024 is expected to be 488.408 billion yuan, with a year-on-year growth of 5.5%, but it faces significant industrial profit declines and energy consumption reductions [23][24] - The need for Zibo to strengthen its county economies is emphasized, with plans to develop 2-3 advantageous industrial chains in each county to enhance overall economic strength [27][28] Group 4 - Yiyuan's ongoing economic initiatives include a focus on industrial development, agricultural modernization, and urban renewal, aiming for high-quality growth [31][32] - The local government is implementing a fruit industry revitalization plan to enhance agricultural productivity and expand the value chain through deep processing [32] - The expansion of chemical parks and the development of new projects by key enterprises like Shandong Yaobang and Ruiyang Pharmaceutical are expected to provide further growth opportunities for Yiyuan [32]

Core Viewpoint - The fluctuating tariff policies in the U.S. have created a challenging environment for the ibuprofen market, with Hendi Pharmaceutical facing significant declines in revenue and profit due to market saturation and external pressures [2][6]. Financial Performance - Hendi Pharmaceutical reported a revenue of 446 million yuan in 2024, a year-on-year decline of 32.75%, marking the largest drop since data tracking began [2]. - The company's net profit attributable to shareholders was 92 million yuan, down 48.02% year-on-year, with a non-recurring net profit of 73 million yuan, down 57.14% [2]. - The raw material drug segment, primarily ibuprofen, accounted for nearly 80% of the company's revenue, making it difficult to pivot to other business areas in the short term [2][4]. Market Dynamics - The demand for ibuprofen surged during the pandemic, peaking in 2023 with revenues of 663 million yuan, but fell sharply in 2024, dropping below levels seen six years prior [3]. - The raw material drug segment's revenue in 2024 was 356 million yuan, a decrease of 35.78%, with a significant drop in sales volume by 37.51% to 2,222.35 tons [4][5]. - The gross margin for the raw material drug segment fell from 36.11% to 21.18% in 2024, indicating increased cost pressures [4]. Business Strategy - Hendi Pharmaceutical has been developing a range of ibuprofen derivative products to maximize market value, including right-handed ibuprofen, which saw a sales increase of 11.43% to 189.45 tons [4][5]. - The company's formulation business, which generated 85 million yuan in 2024, also faced a decline of 17.57% year-on-year, with a gross margin decrease to 59.48% [5]. - The formulation business remains closely tied to ibuprofen, limiting its ability to act as a buffer against market volatility [5]. Industry Challenges - Hendi Pharmaceutical faces intense competition in the global ibuprofen market, with prices remaining low due to market saturation and external factors such as U.S. tariff policies [6][8]. - The company has decided to terminate its planned expansion project for ibuprofen production, reallocating funds to other development projects instead [7][8]. - The U.S. tariff policies have created uncertainty, particularly affecting exports to key markets like India, despite Hendi's low direct exposure to U.S. sales [8][9].

百诺医药在资本市场上有丰富的经历。 IPO日报注意到，百诺医药曾于2016年3月24日登陆新三板挂牌，证券简称为百诺医药，证券代码为 836534，挂牌6年半后，在 2022年12月16日摘牌。 星标 ★ IPO日报 精彩文章第一时间推送 4月17日晚间，证监会官网披露，中信建投对辅导山东百诺医药股份有限公司（下称"百诺医药"）挂牌新三板并在北交所上市进 行了备案登记。 两年多前曾从新三板摘牌，后又创业板IPO失败，如今想重回新三板并在北交所上市的百诺医药怎么样了？ IPO日报注意到，百诺医药的2021年-2023 年营业收入和净利润的年复合增长率分别为43.98％、123.61％，业绩极为亮眼，毛 利率也高达76%以上。 制图：佘诗婕 净利润年复合增长率123.61％ 据悉，百诺医药成立于2000年8月，是一家贯穿药物研发及生产全生命周期的创新型一站式药物研发成果转化运营商，主要业务 分为三大部分，分别为医药研发CRO业务、医药生产CMO业务和原料药生产及销售业务，其中CRO业务以研发成果转化模式为 主。 （ Contract Research Organization ，即合同研究组织，指对外提供专业化药 ...

Core Viewpoint - The article highlights the significant performance of Zijin Mining in Q1 2025, showcasing its revenue growth and profit increase, alongside the upcoming stock unlock events in the A-share market. Group 1: Zijin Mining Performance - Zijin Mining reported a Q1 2025 revenue of 789.28 billion, representing a year-on-year growth of 5.55% and a net profit of 101.67 billion, up 62.39% year-on-year, attributed to improved operational management and increased production of key minerals [3][5]. - The production data indicates a 13% increase in gold output and a 9% increase in copper output, while zinc production saw a 10% decline. The company's gross profit margin reached 59.94%, an increase of 5.44 percentage points year-on-year [5]. Group 2: Stock Unlock Events - Next week, 31 stocks will have their lock-up lifted, with a total unlock market value exceeding 11 billion [8]. - Among the stocks, 10 will have unlock values over 500 million, with Zhuozhao Point Glue and Weijie Chuangxin leading at 1.799 billion and 1.753 billion respectively [9]. - The unlock ratio, which reflects the impact on stock prices, shows that 15 of the 31 stocks have an unlock ratio exceeding 5%, with 8 stocks over 10% [12]. - Zhuozhao Point Glue has the highest unlock ratio at 71.66%, followed by Jindao Technology at 37.5%, and others exceeding 25% [13].

Group 1 - The National Medical Insurance Administration has collected a total of 27.309 billion drug traceability codes, covering 31 provinces and regions in China, with over 95% of designated medical institutions connected [1] - The "Medical Insurance Drug and Consumables Traceability Information Query" function on the National Medical Insurance Service Platform App has seen nearly 500,000 daily users since its launch [1] Group 2 - Tianjin Weiming Bio-Pharmaceutical's core product, interferon α2b spray, has been suspended from procurement in multiple regions due to non-compliance with biological activity standards [2] - The suspension of procurement is expected to impact the company's market share and reputation, highlighting the need for improved quality control [2] Group 3 - HRS-9813 capsules developed by Heng Rui Medicine have received clinical trial approval for the treatment of Idiopathic Pulmonary Fibrosis, with the tablet form also in Phase I trials [3] - The dual formulation development is anticipated to enhance the company's competitiveness in the treatment of this condition [3] Group 4 - WuXi Biologics has completed the sale of its Irish vaccine facility for a total consideration of $499.6 million, which includes $407 million paid at closing and $30 million held in escrow [4] - The transaction is expected to optimize asset allocation and improve cash flow, allowing the company to focus on its core business [4] Group 5 - Xinhua Pharmaceutical reported a revenue increase of 4.51% to 8.466 billion yuan for 2024, but net profit decreased by 5.33% to 470 million yuan due to price reductions of key products [5][6] - The decline in profit despite revenue growth reflects intense competition in the pharmaceutical market, necessitating faster new product development and market expansion to enhance profitability [6]

研发方面，2024年，新华制药研发费用4.13亿元，同比减少1.44%；研发人员数量为828人，较2023年的849人减少21人，其中博士学历17人，硕士学历216 人，本科学历318人、本科以下学历277人。 瑞财经 刘治颖 3月30日，新华制药(SZ000756)发布2024年年度报告，增收不增利。 2024年，新华制药营业收入为84.66亿元，同比增长4.51%，归属于上市公司股东的净利润为4.7亿元，同比减少5.33%；归属于上市公司股东的扣除非经常性 损益的净利润4.48亿元，同比减少2.93%。 据了解，2024年，新华制药营收较2016年已经翻倍，创下历史新高；与此同时，该公司归母净利润却有所下滑，这也是其2013年以来归母净利润首次下滑。 | 项目 | 2024年 | 2023 年 | 变动比例 | | --- | --- | --- | --- | | 研发人员数量(人) | 828 | 849 | (2. 47%) | | 研发人员数量占比 | 11.35% | 11. 95% | (0. 60%) | | 研发人员学历结构 | - | - | - | | 本科以下 | 277 | 330 ...